Literature DB >> 20694513

MCM-2 and MCM-5 expression in gastric adenocarcinoma: clinical significance and comparison with Ki-67 proliferative marker.

Constantinos Giaginis1, Athina Giagini, Gerasimos Tsourouflis, Elisavet Gatzidou, Emmanuel Agapitos, Gregorios Kouraklis, Stamatios Theocharis.   

Abstract

BACKGROUND: Minichromosome maintenance (MCM) proteins are essential components of DNA replication, being related to cell proliferation, and serve as useful biomarkers for cancer screening, surveillance and prognosis. The aim of the present study was to evaluate the clinical significance of MCM-2 and MCM-5 expression in gastric adenocarcinoma in comparison with Ki-67 proliferative marker.
METHODS: MCM-2, MCM-5 and Ki-67 expression was assessed immunohistochemically in 66 tumoral samples of gastric adenocarcinoma patients and was statistically analyzed in relation to clinicopathological characteristics and patient survival.
RESULTS: MCM-2 expression did not show significant associations with any clinicopathological parameters, while Ki-67 expression was merely significantly associated with tumor size (P = 0.0150). MCM-2 and Ki-67 expression were more frequently in intestinal (median values: 67.5 and 60%) compared to diffuse-type (median values: 60 and 45%) gastric adenocarcinoma cases without though reaching statistical significance (P > 0.05). MCM-5 expression was significantly associated with tumor size (P = 0.0295), presence of lymph node metastases (P = 0.0216) and tumor histopathological stage (P = 0.0098). Patients presenting high MCM-5 expression had significantly shorter survival times (log-rank test, P = 0.0042), whereas neither MCM-2 nor Ki-67 expression showed significant prognostic value (log-rank test, P = 0.9618 and P = 0.7174, respectively). In multivariate analysis, patient age, histopathological stage and grade of differentiation, but not MCM-5 expression, were identified as independent prognostic factors (Cox regression analysis, P = 0.0097, P = 0.0195, P = 0.0035 and P = 0.3245, respectively).
CONCLUSIONS: The present study showed that MCM-5 expression was associated with clinicopathological parameters in gastric adenocarcinoma. However, further studies highlighting the distinct impact of the two histopathological types, intestinal and diffuse, are warranted to delineate whether MCMs could be used as diagnostic and prognostic markers in gastric neoplasia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694513     DOI: 10.1007/s10620-010-1348-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  35 in total

Review 1.  MCM proteins in DNA replication.

Authors:  B K Tye
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

2.  A rotary pumping model for helicase function of MCM proteins at a distance from replication forks.

Authors:  Ronald A Laskey; Mark A Madine
Journal:  EMBO Rep       Date:  2003-01       Impact factor: 8.807

Review 3.  Gastric cancer: global pattern of the disease and an overview of environmental risk factors.

Authors:  D Forman; V J Burley
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

Review 4.  Pathology and molecular biology of gastric cancer.

Authors:  Matti Vauhkonen; Hanna Vauhkonen; Pentti Sipponen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

5.  Minichromosome maintenance proteins as biological markers of dysplasia and malignancy.

Authors:  A Freeman; L S Morris; A D Mills; K Stoeber; R A Laskey; G H Williams; N Coleman
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

6.  Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis.

Authors:  Seon-Ah Ha; Seung Min Shin; Hong Namkoong; Heejeong Lee; Goang Won Cho; Soo Young Hur; Tae Eung Kim; Jin Woo Kim
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

Review 7.  MCM proteins as diagnostic and prognostic tumor markers in the clinical setting.

Authors:  Constantinos Giaginis; Stephanie Vgenopoulou; Philippe Vielh; Stamatios Theocharis
Journal:  Histol Histopathol       Date:  2010-03       Impact factor: 2.303

Review 8.  Genetic pathways of two types of gastric cancer.

Authors:  Eiichi Tahara
Journal:  IARC Sci Publ       Date:  2004

9.  Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival.

Authors:  Stamatios Theocharis; Costas Giaginis; Aikaterini Parasi; Alexandra Margeli; John Kakisis; Emmanuel Agapitos; Gregorios Kouraklis
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

10.  Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade.

Authors:  M Burger; S Denzinger; A Hartmann; W-F Wieland; R Stoehr; E C Obermann
Journal:  Br J Cancer       Date:  2007-05-15       Impact factor: 7.640

View more
  28 in total

1.  MCM5 promotes tumour proliferation and correlates with the progression and prognosis of renal cell carcinoma.

Authors:  Binbin Gong; Ming Ma; Xiaorong Yang; Wenjie Xie; Yanping Luo; Ting Sun
Journal:  Int Urol Nephrol       Date:  2019-06-12       Impact factor: 2.370

2.  Expression of minichromosome maintenance 8 in chronic myelogenous leukemia.

Authors:  Lili Cai; Kai Zhao; Xuejie Yuan
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  Comparison of the blood and lymphatic microvessel density of pleomorphic adenoma and Basal cell adenoma.

Authors:  Andresa Borges Soares; Albina Altemani; Thais Ribeiro de Oliveira; Felipe de Oliveira Fonseca Rodrigues; Alfredo Ribeiro-Silva; Danilo Figueiredo Soave; Fabricio Passador-Santos; Suellen Trentin Brum; Marcelo Henrique Napimoga; Vera Cavalcanti de Araújo
Journal:  Clin Med Insights Pathol       Date:  2015-04-19

Review 4.  MCM Paradox: Abundance of Eukaryotic Replicative Helicases and Genomic Integrity.

Authors:  Mitali Das; Sunita Singh; Satyajit Pradhan; Gopeshwar Narayan
Journal:  Mol Biol Int       Date:  2014-10-19

5.  MCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki-67, Bmi1, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions.

Authors:  Bonnie Choy; Amy LaLonde; Jianwen Que; Tongtong Wu; Zhongren Zhou
Journal:  Hum Pathol       Date:  2016-07-29       Impact factor: 3.466

Review 6.  Clinicopathologic significance and prognostic value of Ki-67 expression in patients with gastric cancer: a meta-analysis.

Authors:  Guanying Luo; Yunzhao Hu; Zhiqiao Zhang; Peng Wang; Zhaowen Luo; Jinxin Lin; Canchang Cheng; You Yang
Journal:  Oncotarget       Date:  2017-07-25

7.  Genome wide comparative comprehensive analysis of Plasmodium falciparum MCM family with human host.

Authors:  Abulaish Ansari; Renu Tuteja
Journal:  Commun Integr Biol       Date:  2012-11-01

8.  Over expression of minichromosome maintenance genes is clinically correlated to cervical carcinogenesis.

Authors:  Mitali Das; Shyam Babu Prasad; Suresh Singh Yadav; H B Govardhan; Lakshmi Kant Pandey; Sunita Singh; Satyajit Pradhan; Gopeshwar Narayan
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

9.  A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).

Authors:  George Pentheroudakis; Vassiliki Kotoula; Elena Fountzilas; George Kouvatseas; George Basdanis; Ioannis Xanthakis; Thomas Makatsoris; Elpida Charalambous; Demetris Papamichael; Epaminontas Samantas; Pavlos Papakostas; Dimitrios Bafaloukos; Evangelia Razis; Christos Christodoulou; Ioannis Varthalitis; Nicholas Pavlidis; George Fountzilas
Journal:  BMC Cancer       Date:  2014-02-20       Impact factor: 4.430

10.  The Expression and Prognostic Roles of MCMs in Pancreatic Cancer.

Authors:  Yun-Peng Peng; Yi Zhu; Ling-Di Yin; Jing-Jing Zhang; Song Guo; Yue Fu; Yi Miao; Ji-Shu Wei
Journal:  PLoS One       Date:  2016-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.